Bull Flag Stocks
IRON is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
DISC MEDICINE INC (IRON) Stock Price & Overview
NASDAQ:IRON • US2546041011
Current stock price
68.85 USD
+0.53 (+0.78%)
At close:
68.85 USD
0 (0%)
After Hours:
The current stock price of IRON is 68.85 USD. Today IRON is up by 0.78%. In the past month the price increased by 11.03%. In the past year, price increased by 51.59%.
IRON Key Statistics
52-Week Range40.0001 - 99.5
Current IRON stock price positioned within its 52-week range.
1-Month Range58.35 - 72.4
Current IRON stock price positioned within its 1-month range.
- Market Cap
- 2.627B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.01
- Dividend Yield
- N/A
IRON Stock Performance
Today
+0.78%
1 Week
-4.07%
1 Month
+11.03%
3 Months
-9.80%
Longer-term
6 Months -19.60%
1 Year +51.59%
2 Years +147.31%
3 Years +110.36%
5 Years N/A
10 Years N/A
IRON Stock Chart
IRON Stock Screens
IRON currently appears in the following ChartMill screener lists.
IRON Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is one of the better performing stocks in the market, outperforming 76.52% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
IRON Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IRON. The financial health of IRON is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IRON Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.64
Revenue Reported
EPS Surprise 7.82%
Revenue Surprise %
IRON Forecast & Estimates
19 analysts have analysed IRON and the average price target is 102.17 USD. This implies a price increase of 48.4% is expected in the next year compared to the current price of 68.85.
Analysts
Analysts86.32
Price Target102.17 (48.4%)
EPS Next Y-21.47%
Revenue Next YearN/A
IRON Groups
Sector & Classification
IRON Financial Highlights
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS decreased by -50.63% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-212.18M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.3% | ||
| ROE | -28.68% | ||
| Debt/Equity | 0.04 |
Chartmill High Growth Momentum
EPS Q2Q%-67.35%
Sales Q2Q%N/A
EPS 1Y (TTM)-50.63%
Revenue 1Y (TTM)N/A
IRON Ownership
Ownership
Inst Owners96.27%
Shares38.16M
Float31.94M
Ins Owners0.66%
Short Float %17.09%
Short Ratio7.55
IRON Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IRON
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
IPO: 2020-08-12
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 155
Phone: 16176749274
DISC MEDICINE INC / IRON FAQ
Can you describe the business of DISC MEDICINE INC?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
What is the stock price of DISC MEDICINE INC today?
The current stock price of IRON is 68.85 USD. The price increased by 0.78% in the last trading session.
Does DISC MEDICINE INC pay dividends?
IRON does not pay a dividend.
How is the ChartMill rating for DISC MEDICINE INC?
IRON has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists IRON stock?
IRON stock is listed on the Nasdaq exchange.
Can you provide the number of employees for DISC MEDICINE INC?
DISC MEDICINE INC (IRON) currently has 155 employees.
What is the next earnings date for IRON stock?
DISC MEDICINE INC (IRON) will report earnings on 2026-05-07.